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Terapiendoskopimerupakankaedahutamadalamrawatanpenyakit “upper gastrointestinal 
bleeding” (UGIB). Walaupunterdapatkemajuandalambidangterapiendoskopi, 
kadarkematianpesakit UGIB tetapdalamlinkungan 10% untukbeberapadekad yang lalu. 
Kajianinibermatlamatmengenalpasti “prevalence” 
hasilselepasterapiendoskopiuntuklukaperutberdarah. 
KaedahKajian:  Iniadalahkajianrekodsecararetrospektifbagipesakit yang menjalani 
“emergency upper endoscopy for UGIB” dari Mac 2014 ke Mac 2019 di Hospital 
Serdang, Selangor. Data diperolehidarirekodsuite endoskopidanprevalen“permanent 
haemostasis”, endoskopiulangan, angio-embolization, 
pembedahandankematiandihitung-kirakan. 
Keputusan:  Seramai204 pesakit yang telahmenjalani “emergency upper endoscopic 
therapy for UGIB” dimasukkankedalamkajian kami. Lebihdariseparuhpesakit 113 
(55.4%) berjayamencapai “permanent haemostasis” selepasrawatan “endoscopic 
therapy” pertamamanakala 84 (41.2%) 
terpaksamenjalaniendoskopiulangandisebabkanpendarahansemulaluka. 
Sebahagiankecilterpaksamenjalanipembedahan 10 (4.9%) sementaracuma 3 (1.5%) 
menjalaniangio-embolization. Daripada 204 pesakit yang dimasukkan, terdapat 34 
(16.7%) mortalitidanjangkamasaadmisi di wad adalah 5 hari. 
Kesimpulan:  Dari kajian kami, kami dapatmenyimpulkanbahawa “permanent 
haemostasis” hasildenganprevalen paling tinggiselepasterapiendoskopi di hospital kami. 
v 
Walaubagaimanapun, kitaperlumengurangkankadarendoskopiulangan kami 
keranamasihlebihtinggidaripada data negaramembangun yang lain. 
 
ABSTRACT 
Background and objectives:  Endoscopic therapy remains the mainstay in treatment of 
upper gastrointestinal bleeding (UGIB). Despite the advancement in endoscopic 
therapy, the mortality rate for UGIB has remained constant at about 10% for the past 
few decades. This study aims to determine the prevalence of outcomes post endoscopic 
therapy in bleeding peptic ulcers. 
Methods:  This is a retrospective record review of patients who underwent emergency 
upper endoscopy for UGIB from March 2014 to March 2019 in Hospital Serdang, 
Selangor. Data was collected from endoscopic suite records and the prevalence of 
permanent haemostasis, re-endoscopy, angio-embolization, surgery and 30-day 
mortality was calculated. 
Results:  A total of 204 patients who underwent emergency upper endoscopic therapy 
for UGIB were included in our study. More than half of the patients 113 (55.4%) 
achieved permanent haemostasis after initial endoscopic therapy whilst 84 (41.2%) had 
to undergo re-endoscopy due to re-bleeding ulcer. A small percentage had to undergo 
surgery 10 (4.9%) while only 3 (1.5%) underwent angio-embolization. Out of 204 
patients included, there was 34 (16.7%) mortalities and the median length of stay was 5 
days. 
Conclusion:  From our study, we can conclude that permanent haemostasis is the 
outcome with highest prevalence after endoscopic therapy for UGIB in our centre. 
vi 
However, we should strive to reduce our rate of re-endoscopy as it is not up to par with 
data from other developing countries. 
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CHAPTER ONE:INTRODUCTION 
1.1 LITERATURE REVIEW 
Acute Upper Gastrointestinal Bleeding (UGIB) remains a common cause of 
hospitalization in Malaysia. The incidence is approximately 72 per 100000 in Malaysia 
(Cheng JLS et.al, 2001). Despite important advances made in the management of non-
variceal UGIB, the overall mortality has remained constant at 10% for the past few 
decades (Ruigómez et.al, 2000, Rockall et.al, 1995, Allan and Dykes, 1976, Fleischer, 
1983). This may in part be due to the fact that older patients, who have advanced 
cardiovascular, respiratory, or cerebrovascular disease that puts them at increased risk 
of death, now comprise a much higher proportion of cases. 
UGIB refers to bleeding from any point proximal to the duodeno-jejunal flexure 
(Ligament of Treitz). UGIB can be divided into variceal and non-variceal bleeding. 
Variceal bleeding can be caused by either oesophageal varices or fundal varices. Non-
variceal bleeding can be further subdivided into haemorrhagic gastritis, peptic ulcer 
bleeding, tumour/polyp bleeding or arterio-venous malformation bleeding. 
Patients come to the hospital complaining of frank haematemesis, coffee ground 
vomiting and/or melaena. Fresh bleeding per rectum is usually indicative of lower GI 
bleeding, however massive UGIB can present with passing of red blood clots per-
rectally. Haemodynamic instability may also feature, with patients presenting with 
dizziness, syncope or in hypovolaemic shock.  
Upper endoscopy is crucial in the diagnosis, stratification, and management of 
patients with bleeding ulcers, and endoscopic haemostatic therapy is the mainstay of 
treatment in patients with endoscopic findings that predict an increased risk of further 
bleeding (Laine and McQuaid, 2009).  
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Once source of bleeding is identified, the ulcer is stratified using the Forrest 
Classification which differentiates high risk of re-bleeding ulcers from low risk of re-




In addition to endoscopic therapy, acid suppressors are administered to patients, 
particularly proton pump inhibitors. Several studies have examined the role of acid 
suppression given before or after endoscopy (with or without therapeutic intervention) 
(Dorwardet.al, 2006). 
The currently available endoscopic haemostatic methods include injection 
therapy, thermal coagulation, and mechanical therapy. Among these approaches, 
injection of epinephrine is the most popular endoscopic method used to stop bleeding 
because of its safety, low cost, and easy application. Studies have shown that adding a 
second endoscopic therapy to epinephrine injection might improve haemostatic efficacy 
and patient outcomes (Park et.al, 2004, Chung et.al, 1997, Pescatoreet.al, 2002). 
 
3 
The most favourable outcome post endoscopic therapy is of course the control of 
bleeding. However in some instances the bleeding does not stop after the initial 
endoscopic therapy thus requiring further intervention in the forms of either repeat 
endoscopic therapy, angio-embolization or surgery. Ultimately, if the bleeding cannot 



















1.2 RATIONALE OF STUDY 
Peptic ulcers remain the most common cause of UGIB, accounting for 30-60% 
of UGIB hospitalizations. Endoscopic therapy remains the mainstay for treatment as it 
reduces re-bleeding rate, need for surgery, morbidity and mortality of bleeding peptic 
ulcers.  
The overall mortality rate of 10% is a cause for concern. 
With the advancement in management of bleeding peptic ulcers, the outcome of 
patients may differ from centre to centre depending on the availability of treatment and 
surgeon’s expertise. 
Apart from that, currently there is no data that shows the outcomes of 













CHAPTER TWO: STUDY PROTOCOL 
2.1 DOCUMENTS SUBMITTED FOR ETHICAL APPROVAL 
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Acute Upper Gastrointestinal Bleeding (UGIB) remains a common cause of 
hospitalization in Malaysia. The incidence is approximately 72 per 100000 in Malaysia 
[1]. Despite important advances made in the management of non-variceal UGIB, the 
overall mortality has remained constant at 10% for the past few decades [2-5]. This may 
in part be due to the fact that older patients, who have advanced cardiovascular, 
respiratory, or cerebrovascular disease that puts them at increased risk of death, now 
comprise a much higher proportion of cases. 
UGIB refers to bleeding from any point proximal to the duodeno-jejunal flexure 
(Ligament of Treitz). UGIB can be divided into variceal and non-variceal bleeding. 
Variceal bleeding can be caused by either oesophageal varices or fundal varices. Non-
variceal bleeding can be further subdivided into haemorrhagic gastritis, peptic ulcer 
bleeding, tumour/polyp bleeding or arterio-venous malformation bleeding. 
Patients come to the hospital complaining of frank haematemesis, coffee ground 
vomiting and/or melaena. Fresh bleeding per rectum is usually indicative of lower GI 
bleeding, however massive UGIB can present with passing of red blood clots per-
rectally. Haemodynamic instability may also feature, with patients presenting with 
dizziness, syncope or in hypovolaemic shock.  
Upper endoscopy is crucial in the diagnosis, stratification, and management of 
patients with bleeding ulcers, and endoscopic haemostatic therapy is the mainstay of 
treatment in patients with endoscopic findings that predict an increased risk of further 
bleeding [6].  
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Once source of bleeding is identified, the ulcer is stratified using the Forrest 
Classification which differentiates high risk of re-bleeding ulcers from low risk of re-




In addition to endoscopic therapy, acid suppressors are administered to patients, 
particularly proton pump inhibitors. Several studies have examined the role of acid 
suppression given before or after endoscopy (with or without therapeutic intervention) 
[8]. 
The currently available endoscopic haemostatic methods include injection 
therapy, thermal coagulation, and mechanical therapy. Among these approaches, 
injection of epinephrine is the most popular endoscopic method used to stop bleeding 
because of its safety, low cost, and easy application. Studies have shown that adding a 
second endoscopic therapy to epinephrine injection might improve haemostatic efficacy 




The most favourable outcome post endoscopic therapy is of course the control of 
bleeding. However in some instances the bleeding does not stop after the initial 
endoscopic therapy thus requiring further intervention in the forms of either repeat 
endoscopic therapy, angioembolization or surgery. Ultimately, if the bleeding cannot be 


























Justification of Study 
Peptic ulcers remain the most common cause of UGIB, accounting for 30-60% 
of UGIB hospitalizations. Endoscopic therapy remains the mainstay for treatment as it 
reduces re-bleeding rate, need for surgery, morbidity and mortality of bleeding peptic 
ulcers.  
The overall mortality rate of 10% is a cause for concern. 
With the advancement in management of bleeding peptic ulcers, the outcome of 
patients may differ from centre to centre depending on the availability of treatment and 
surgeon’s expertise. 
Apart from that, currently there is no data that shows the outcomes of 


















Primary (Specific) objective 
To determine the prevalence of permanent haemostasis and rate of re-endoscopy after 
initial endoscopic therapy for bleeding peptic ulcers in Hospital Serdang. 
 
Secondary objectives 
1. To determine the prevalence of angio-embolization and surgery after initial 
endoscopic therapy for bleeding peptic ulcers in Hospital Serdang.  
2. To describe the demographics in patients with bleeding peptic ulcers in Hospital 
Serdang. 
3. To describe the length of stay of patients with bleeding peptic ulcers in Hospital 
Serdang. 
4. To describe the 30-day mortality rate [12] of patients with bleeding peptic ulcers 
in Hospital Serdang. 
 
Research Questions 
What is the proportions of outcomes after receiving endoscopic therapy for bleeding 
peptic ulcers in Hospital Serdang? 
What is the average length of hospital stay for patients that receive endoscopic therapy 
for bleeding peptic ulcers? 
What is the mortality rate of patients that receive endoscopic therapy for bleeding peptic 




This is a retrospective record review of patients who underwent emergency upper 
endoscopy from March 2014 to March 2019 in Hospital Serdang, Selangor. 
 
Study Variables 
• Outcome i.e.; permanent haemostasis, re-endoscopy, angio-embolization, 
surgery, mortality 
• Type of endoscopic therapy i.e.; single or dual 
• Demographics e.g.: age, race, gender, co-morbidities 
• Length of hospital stay in days 
 
Place of Study 
This study will be conducted in Hospital Serdang, Selangor. 
 
Study population 
Patients who underwent upper endoscopy from March 2014 to March 2019 in Hospital 






- Higher risk of re-bleeding ulcers based on the Forrest Classification (Forrest 1A, 
1B, 2A, 2B). If there are multiple ulcers present, the ulcer with the highest risk of re-
bleed will be taken into account. 
- Underwent emergency upper endoscopy 
- Age above 18 years old (underaged) 
Exclusion criteria 
- Presence of another bleeding site e.g.: variceal bleeding, tumor bleeding, AVM, 
hemangioma bleeding, hemorrhagic gastritis etc. 
 
Sampling method 
Universal sampling. Patients who had upper endoscopy done for high risk of re-
bleeding ulcers are selected from the scope suite records from March 2014 to March 
2019. 
Sample Size 
Using a single proportion formula, the sample sizes based on the objectives were 
calculated. Out of the available data, the largest and most feasible sample size required 
was 185. It was based on the objective in which permanent haemostasis was achieved 
after initial endoscopic therapy, whereby the proportion was 9.1% based on a previous 
study by Zaltman et al. 2002[14]. As such, the proportions for angio-embolization and 
surgery were not calculated as there is no previous data to base our calculation on. The 
precision was set at 0.05 (5%). After considering 10% no response rate, the required 






Outcome Reference P n n + 10% 
Permanent 
haemostasis 
Zaltman et al. 
2002 
0.86 185 204 
Re-endoscopy Zaltman et al. 
2002 










Conduct of study 
1. After ethics committee approval, a list of patients who underwent emergency 
upper endoscopy from March 2014 to March 2019 will be collected from the 
endoscopic suite records, Hospital Serdang. 
2. Patients who fulfil the inclusion and exclusion criteria will be recruited into the 
study. Patient’s data will be obtained by retrospective study of patients 
electronic medical records and entered into a data collection form. (appendix A) 
3. Patient’s final outcome will then be recorded. I.e.: if patient underwent 
endoscopic therapy, then surgery and ultimately succumbed to death, his final 
outcome will be under mortality. 
4. Patients who did not turn up for follow up, would be contacted to ascertain 
whether patients had passed away during the 30-day mortality period. If patients 
are unable to be contacted, they will be dropped out from the study. 
 
 
Statistical Analysis Plan 
The analyses will be performed using the IBM SPSS Statistics Version 19.0 
(IBM Corp, Armonk, NY). The data will be manually entered into the software before 
the cleaning process takes place. The cleaning process is crucial to prevent any errors 
that may skew the results. After that, the actual analysis process will be carried out.  
Numerical data were presented with mean and standard deviation if normality 
assumption were found fulfilled, otherwise median and interquartile range. Categorical 
variables were presented as frequency and percentage. 
15 
Pearson Chi Square and Fisher Exact test were used to test the association 
between mortality and underlying medical illness (Hypertension, Diabetes Mellitus, 
Cardiovascular Disease, Ischemic Heart Disease and Chronic Kidney Disease). All the 
tests were two sided and p value less than 0.05 were considered statistically significant. 
 
Ethical Considerations 
Ethical approval will be applied from MREC KKM. This study will be registered with 
the NMRR and JEPEM USM, in compliance with current NIH guideline.  
Status of application with NMRR and JEPEM USM – approved. 
The study will be conducted in compliance with ethical principles outlined in the 
Declaration of Helsinki, Malaysian GCP Guideline and CRC’s standard operating 
procedures. 
 
Privacy and Confidentiality 
All data collected will be confidential. The author will ensure that the subject’s 
anonymity is maintained. Patient’s records and documents that could identify subject 
will be kept protected, respecting the privacy and confidentiality of individuals in 
accordance with local data protection regulations.  
All electronic data will be identified by unique study numbers only, thereby 
ensuring that the subject’s identity remains confidential. The subject identification list 
with complete identification information (participant’s name, contact number) will be 
kept protected and will be destroyed at the end of the study. 
16 
The data for publication will be the responsibility of the author and duration of 
data storage will be 2 years after publication as per GCP requirements. 
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Data Collection FormAppendix A 
Anonymous Study ID : 
Sex : M / F 

































































































Length of Hospital Stay : 
 
